Oklahoma Breakthrough Therapy Act establishes requirements for ibogaine clinical trials, intellectual property rights, and funding.
The Oklahoma Breakthrough Therapy Act establishes requirements for drug developers conducting ibogaine clinical trials within the state. It mandates that drug developers provide detailed descriptions of their trials, ensure broad access to ibogaine treatment, and match state funding with equal additional funding. The act also requires the State Department of Health to negotiate contracts that include provisions on intellectual property, proprietary information, and administration protocols.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.